Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: new + cancer + brain  Related to the article below (Last Update: 8/5/2008)

YM BIOSCIENCES REPORTS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC ...
FOXBusiness -
We intend to file for registration trials in 2008 for patients with non small cell lung cancer (NSCLC) and for those with brain metastases because of ...YMI

Telegraph.co.uk
Vitamin C Shows Promise as Cancer Treatment
Forbes, NY - 32 minutes ago
The mice had ovarian, pancreatic and brain cancer. It's not clear why some tumors are immune to the treatment and others are not, Levine said, ...
Vitamin C jabs may combat cancer New Scientist (subscription)
Vitamin C 'breakthrough' in war on cancer Scotsman
Vitamin C Injections Can Destroy Cancer TheMedGuru
ABC News - Discover Magazine
all 103 news articles »
More drugs, less couch
Minneapolis Star Tribune, MN -
But the older the child is, the less effective the treatment -- and by age 9, brain-eye connections are pretty well set. The new approach: Implantable ...

Canada.com
Genetic discovery offers hope to family with legacy of cancer
Canada.com, Canada -
While she was diagnosed at 25, her mother and aunt were diagnosed with breast cancer in their 30s. Her sister's brain tumour was discovered at age nine and ...
Genetic discovery may lead to new blood test for people at high ... Canada NewsWire (press release)
HOSPITAL FOR SICK CHILDREN Canada NewsWire (press release)
all 62 news articles »

Voice of America
Ten Percent of Healthy People Injured from Silent Strokes
Voice of America -
This week, we will tell about a brain injury known as silent stroke. We will also tell about melanoma -- the most deadly form of skin cancer. ...

PC World
The Selfish Video Game: Play Games, Change Your Biology?
PC World -
Now a new study from non-profit health researcher HopeLab (which blends custom-tailored video games with medical cancer treatment) published in the medical ...
Study Shows Playing Video Games Can Change Behavior, Biology PR Newswire UK (press release)
all 13 news articles »
Nanomagnets tackle cancer
Science News -
The most advanced trial is currently studying some 65 patients with late-stage, recurrent glioblastoma multiforme, a type of brain cancer. ...
Pentagon spends $300M to study troops' stress, trauma
USA Today -
The money ? the most spent in one year on military medical research since a $210 million breast cancer study in 1993 ? will fund 171 research projects on ...

The Money Times
Cell phone warning: hands off
Buffalo News,  United States - Aug 4, 2008
Some said any type of cancer warning is unnerving. ?When you hear the words ?cancer,? ?brain tumor,? it?s pretty serious. It scares you. ...
Debate continues over health hazards of cell phones Gustine Press-Standard
Cell phone use, cancer risk unknown; memo raises alarm El Paso Times
all 36 news articles »
Prominent Chicago Sun-Times Political Columnist Robert Novak ...
MarketWatch -
... he was recently diagnosed with a brain tumor. Mr. Novak, 77, will undergo radiation and chemotherapy at the National Cancer Institute in Washington. ...OTC:SUTM
Source: Google News

… , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer -
J Li, C Yen, D Liaw, K Podsypanina, S Bose, SI … - Science, 1997 - sciencemag.org
... Alert me when: new articles cite this article. ... PTEN, a Putative Protein Tyrosine
Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer. ...

… a new member of the SRCR superfamily, on chromosome 10 q 25. 3?26. 1 is deleted in malignant brain … -
J Mollenhauer, S Wiemann, W Scheurlen, B Korn, Y … - Nature Genetics, 1997 - nature.com
... protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. ...
A new bacteriophage P1-derived vector for the propagation of large ...

[CITATION] … and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada …
R Stupp, WP Mason, MJ van den Bent, M Weller, B … - N Engl J Med, 2005 - Mass Med Soc

Evaluating cluster alarms: a space-time scan statistic and brain cancer in Los Alamos, New Mexico -
M Kulldorff? - American Journal of Public Health, 1998 - pubmedcentral.nih.gov
... 1998 September; 88(9): 1377?1380. Copyright notice. Evaluating cluster alarms: a
space-time scan statistic and brain cancer in Los Alamos, New Mexico. ...

Identification of a Cancer Stem Cell in Human Brain Tumors -
SK Singh, ID Clarke, M Terasaki, VE Bonn, C … - Cancer Research, 2003 - AACR
... In this report, we have identified a new population of cancer stem cells
in brain tumors of different phenotypes. These tumor stem ...

… Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study … -
MJ van den Bent, MJB Taphoorn, AA Brandes, J … - Journal of Clinical Oncology, 2003 - jco.ascopubs.org
... for Research and Treatment of Cancer Brain Tumor Group ... sectional contrast-enhancing
tumor area, new tumor on ... according to the National Cancer Institute common ...

The New WHO Classification of Brain Tumours -
P Kleihues, PC Burger, BW Scheithauer - Brain Pathology, 1993 - Blackwell Synergy
Page 1. Brain Pathology 3: 255268 (1 993) The New WHO Classification of Brain Tumours
Paul Kleihues 1, Peter C. Burger 2 and Bernd W. Scheithauer 3 ...

Shared Genetic Susceptibility to Breast Cancer, Brain Tumors, and Fanconi Anemia -
K Offit, O Levran, B Mullaney, K Mah, K Nafa, SD … - jnci, 2003 - jnci.oxfordjournals.org
... The co-occurrence of brain tumors, Fanconi anemia, and breast cancer observed in
one of these kindreds constitutes a new syndromic association. ...

[PDF] NEW FUNCTIONS FOR THE MATRIX METALLOPROTEINASES IN CANCER PROGRESSION -
M Egeblad, Z Werb - Nature Reviews Cancer, 2002 - microarray.princeton.edu
... They are kept inactive by an interaction NEW FUNCTIONS FOR THE MATRIX
METALLOPROTEINASES IN CANCER PROGRESSION Mikala Egeblad and Zena Werb ...
-

Identification of human brain tumour initiating cells -
SK Singh, C Hawkins, ID Clarke, JA Squire, J Bayani … - Nature, 2004 - Mass Med Soc
... Two new reports expand the evidence base. ... Identification of human brain tumour
initiating cells. ... Gastric cancer originating from bone marrow-derived cells. ...

Source: Google Scholar
 
 

New imaging technique shows early in treatment if brain cancer therapy is effective

Article continues below and (thank you)
 
A special type of MRI scan that measures the movement of water molecules through the brain can help doctors determine halfway through treatment whether it will successfully shrink the tumor or a patient's cancer will continue to grow, a new study shows. The test identifies after only three weeks of treatment - more than two months earlier than traditional tests -- who is responding to the chemotherapy or radiation.

Researchers at the University of Michigan Comprehensive Cancer Center developed the assessment, which they call a functional diffusion map. They used a magnetic resonance imaging scan that tracks the diffusion, or movement, of water through the brain and mapped the changes in diffusion from the start of therapy to three weeks later. The tumor cells restrict the movement of water, so as those cells die, water diffusion changes.

In the study of 34 people with a type of brain tumor called high grade glioma, the researchers found that they could predict after three weeks, based on the functional diffusion map, which cancers would respond to the treatment and which cancers would continue to grow. These predictions corresponded to a significant difference in how long the patients lived.

Results of the study appear the week of Oct. 31 in the early online edition of the Proceedings of the National Academy of Sciences.

High grade gliomas have a high mortality rate, with people surviving only an average of 12 months after diagnosis. Typically, patients receive six to seven weeks of treatment, followed by a traditional MRI scan six weeks after completing therapy to determine if the tumor shrank. If the cancer did not respond to the treatment, a new approach may be tried.

"An early measure of tumor response such as this functional diffusion map could help doctors identify during the course of treatment who might benefit from a second-line therapy, sparing patients from a grueling treatment regimen that's not working," says senior study author Brian Ross, Ph.D., professor of radiology and biological chemistry at the U-M Medical School and co-director of the Molecular Imaging Program at the U-M Comprehensive Cancer Center. "Just as importantly, this finding opens up the opportunity to study not only if treatment is unsuccessful, but where in the tumor it is not succeeding. If this is the case, we can use our sophisticated radiation planning techniques to target higher radiation doses to the regions that are not responding," says study author Theodore Lawrence, M.D., Ph.D., Isadore Lampe Professor and Chair of Radiation Oncology at the U-M Medical School.

In the study, 34 participants with late-stage diffuse high grade glioma, a type of brain tumor, underwent diffusion MRI before beginning a new treatment involving chemotherapy, radiation therapy or a combination. Three weeks later, they had another diffusion MRI. Eight to ten weeks after that, the participants underwent standard MRI to determine whether their tumor responded to the therapy.

At three weeks into treatment - more than two months before the final MRI scan - researchers could identify which patients would have a response to therapy over those with progressive disease. This corresponded to patients' survival, with those classified as having progressive disease living an average 8.2 months while those with a response to treatment lived an average 18.2 months.

In addition, the time until the cancer began to progress was later in the group classified at three weeks by the functional diffusion map as having a partial response or stable disease, 7.3 months compared to 4.3 months for those identified as having progressive disease.

The researchers also looked at standard predictive factors of whether a patient is likely to do well on a therapy - factors such as age, tumor location and tumor size - but found the functional diffusion map was the only accurate predictor of overall survival.

"When the median survival for this type of cancer is less than 52 weeks, waiting an extra 10 weeks to know if treatment is working is a significant amount of time. We hope that functional diffusion mapping will eventually allow oncologists to manage each patient's treatment based on real time evaluation of cellular response to therapy," says study author Suresh Mukherji, M.D., professor of radiology and otolaryngology and division director of neuroradiology at the U-M Medical School.

The researchers believe the test may be useful for other types of cancer, including breast, head and neck, rectal, prostate and liver. The functional diffusion map is not yet available for routine use in clinic.

Additional U-M study authors are Daniel Hamstra, M.D., a resident in radiation oncology; Thomas Chenevert, Ph.D., professor of radiology; Bradford Moffat, Ph.D., assistant professor of radiology; Timothy Johnson, Ph.D., adjunct assistant professor and assistant research scientist in biostatistics; Charles Meyer, Ph.D., professor of radiology; Douglas Quint, M.D., professor of radiology; Stephen Gebarski, M.D., professor of radiology; Xiaoying Fan, a research technician in radiology; Christina Tsien, M.D., assistant professor in radiation oncology; Larry Junck, M.D., professor of neurology; and Alnawaz Rehemtulla, Ph.D., associate professor of radiation oncology and radiology.

Funding for the study was from the National Cancer Institute and the Charles A. Dana Foundation.

The University of Michigan holds a patent on this MRI diffusion technology and has licensed the commercialization rights to Molecular Therapeutics of Ann Arbor, in which Ross and Rehemtulla have a financial interest. A diffusion MRI can be performed on a standard MRI machine using a special workstation to compute the diffusion map. A workstation is being developed by Cedara Software Corp. of Ontario, Canada. Ross, Rehemtulla and Chenevert, as inventors of this technology, would stand to benefit financially from any commercial products.

Patients seeking more information about brain cancer treatment options can call the Cancer AnswerLine at 800-865-1125, or visit http://www.cancer.med.umich.edu/learn/brain.htm.

Reference: Proceedings of the National Academy of Sciences, doi/10.1073/pnas.0508347102

Nicole Fawcett
nfawcett@umich.edu

Kara Gavin
kegavin@umich.edu

University of Michigan Health System
umich.edu
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page